145P Characterising homologous recombination deficiencies in gliomas

Read full text Summarise with VIRAT
Authors: Natalie Southi, H-W. Sim, John P. Grady, Mandy L. Ballinger, D.M. Thomas, Subotheni Thavaneswaran
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Recurrent gliomas, whether isocitrate dehydrogenase (IDH) mutant or wildtype, have limited effective treatments, supporting evaluation of biomarker-guided therapies. IDH mutations drive accumulation of 2-hydroxyglutarate, creating vulnerability within DNA damage response pathways by inducing homologous recombination deficiency (HRD). In preclinical models, HRD has been associated with sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition and appears reversible with IDH inhibition. Accurate characterisation of HRD in gliomas may inform its utility as a therapeutic biomarker.

Fields of Study & Subjects

Glioma Diagnosis and Treatment PARP inhibition in cancer therapy Chromatin Remodeling and Cancer

Publication details

Journal / source
ESMO Open
Volume
11
Pages
106288–106288
Publication date
1 April 2026
Language
EN